Skip to content
TrialMatch
Sign up
Recruiting Phase 2 / Phase 3

Canagliflozin Targeting Vascular Inflammation

Create a profile to match View the full record on ClinicalTrials.gov

About this study

CANTOR SING is a pilot single center double blinded randomized study. The investigators will compare the effect of canagliflozin (300 mg daily - intervention arm) vs. placebo (control group) on the FDG aortic uptake in patients with stable CAD (over 60 days post-myocardial infarction) after a 6-month period of treatment. The investigators plan to enroll 8 patients in each arm (total sample size: 16 patients). Primary endpoint is the change in FDG aortic uptake between baseline and 6 months in each arm.

Condition
Diabetes Type 2, Coronary Artery Disease
Tested
Canagliflozin, Placebo
Sponsor
Ottawa Heart Institute Research Corporation

Who can join

Age
18 years and older
Sex
All sexes
Healthy volunteers
Not accepted

Inclusion 5

  • Minimum age: 18 years
  • Study condition: Diabetes Type 2, Coronary Artery Disease
  • 1\) Stable CAD (over 60 days post-myocardial infarction).
  • 2\) Diabetes
  • 3\) given informed consent.

Exclusion 12

  • severe LV dysfunction (EF\<50%);
  • decompensated heart failure;
  • active infection (e.g. pneumonia, active skin infections, and on antibiotics);
  • active inflammatory conditions (e.g. rheumatoid arthritis, chronic inflammatory bowel disease, SLE, systemic anti-inflammatory therapy (e.g. prednisone, methotrexate));
  • pregnancy (all women of child bearing potential will have a negative BHCG test;
  • breastfeeding;
  • Women of childbearing potential who refuse to use two forms of contraception (this includes at least one form of highly effective and one effective method of contraception) throughout the study OR men capable of fathering a child who refuse to use contraception.
  • glomerular filtration rate (GFR) \<50 ml/min/1.72m2;
  • Use of p-glycoprotein inhibitor (e.g. cyclosporine, verapamil, or quinidine) or a strong CYP3A4 inhibitor (e.g. ritonavir, clarithromycin, or ketoconazole);
  • Hemoglobin \< 105(women) \<110 (men) g/L; WBC \< 3.0x 10(9)/L, platelet count\< 110x 10(9)/L;
  • Patient with a history of cirrhosis, chronic active hepatitis or severe hepatic disease or with alanine aminotransferase (ALT) levels greater than 3 times the upper limit of normal.
  • unable to give informed consent;

Where

1 site, 1 recruiting

University of Ottawa Heart Institute

Ottawa, Ontario, Canada

Recruiting

Contact

Potential match only. Final eligibility is determined by the study team.